Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Michael BöhmStefan D AnkerFelix MahfoudLucas LauderGerasimos S FilippatosJoao Pedro FerreiraStuart J PocockMartina BrueckmannIlias SaloustrosElke SchülerChristoph WannerFaiez ZannadMilton PackerJaved ButlerPublished in: European heart journal (2022)
URL: https://www.clinicaltrials.gov Unique identifier: NCT03057951.